Program
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001
Also written as “ISB 2001” and “ABBV-2001”.
In AbbVie’s pipeline, BCMA, CD38, CD3
. Its studies are mostly in Multiple Myeloma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 11 open or running | phase 2since Mar 19, 2025 | Mar 19, 2025 | Dec 2035phase 2 · NCT06892522 |
| Ichnos Sciencesits history only | 11 open or running | phase 1since May 4, 2023 | May 4, 2023 | Jul 2027phase 1 · NCT05862012 |
- Named in AbbVie’s own pipeline as
ABBV-2001 (ISB 2001)
, phase 1, as of Jul 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 4, 2023First study: phase 1 study in Multiple MyelomaNew to Ichnos SciencesIchnos Sciences · NCT05862012 · 200 planned · United States, Australia, France and more
- Mar 19, 2025AbbVie’s first study: phase 2 study in Multiple MyelomaNew to AbbVieAbbVie · NCT06892522 · 602 planned · United States, Australia, Israel and more
Ahead
- Jul 2027Primary completion: phase 1 study in Multiple MyelomaIchnos Sciences · NCT05862012
- Dec 2035Primary completion: phase 2 study in Multiple MyelomaAbbVie · NCT06892522
TargetBeta
“BCMA, CD38, CD3”the company's pipeline, read by Claude · source
“A T-cell engager and trispecific antibody targeting the two tumor-associated antigens (TAAs) CD38 and human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), and the T-cell surface antigen CD3, ”NCIt, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06892522Multiple Myeloma · United States, Australia, Israel and more | 2 | Recruiting | AbbVie | Dec 2035 | 602 |
| NCT05862012Multiple Myeloma · United States, Australia, France and more | 1 | Recruiting | Ichnos Sciences | Jul 2027 | 200 |
How it is read
Names in the registry
- “ISB 2001”, 2 entries
- “ABBV-2001”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.